Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease. A 3D [18F]dopa-PET study

Brain

Volumn 122, Issue 9, 1999, Pages 1637-1650

  Rakshi, James S ^a,d   Uema, T ^a   Ito, K ^a,c   Bailey, D L ^a   Morrish, P K ^a   Ashburner, J ^b   Dagher, A ^a   Jenkins, I H ^a   Friston, K J ^b   Brooks, D J ^a,b  

^a MRC Cyclotron Unit   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

3D 18F dopa; Extrastriatal; Focal changes; Parkinson's disease; Progression

Indexed keywords

DOPA; FLUORINE 18;

ADULT; AGED; ARTICLE; BRAIN MAPPING; BRAIN SIZE; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DOPAMINERGIC ACTIVITY; FRONTAL LOBE; HUMAN; MESENCEPHALON; NERVE CELL DEGENERATION; NORADRENERGIC NERVE; PARKINSON DISEASE; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEROTONINERGIC NERVE CELL; THREE DIMENSIONAL IMAGING;

EID: 0032870202     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/122.9.1637     Document Type: Article

References (71)

1. Agid Y, Javoy F, Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nat New Biol 1973; 245: 150-1.
2. Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden CD, Fahn S, editors. Movement disorders 2. London: Butterworths; 1987. p. 166-230.
3. Andersson K, Schwarcz R, Fuxe K. Compensatory bilateral changes in dopamine turnover after striatal kainate lesion. Nature 1980; 283: 94-6.
4. Badawi RD. 3D-Mode acquisition in clinical PET [editorial]. Nuc Med Commun 1997; 18: 801-4.
5. Bailey DL. 3D acquisition and reconstruction in positron emission tomography. [Review]. Ann Nucl Med 1992; 6: 123-30.
6. Bailey DL, Meikle SR. A convolution-subtraction scatter correction method for 3D PET. Phys Med Biol 1994; 39: 411-24.
7. Bannon MJ, Roth RH. Pharmacology of mesocortical dopamine neurons. [Review]. Pharmacol Rev 1983; 35: 53-68.
8. Bannon MJ, Reinhard JF Jr, Bunney EB, Roth RH. Unique response to antipsychotic drugs is due to absence of terminal autoreceptors in mesocortical dopamine neurones. Nature 1982; 296: 444-6.
9. Bannon MJ, Poosch MS, Xia Y, Goebel DJ, Cassin B, Kapatos G. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc Natl Acad Sci USA 1992; 89: 7095-9.
10. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20: 415-55.
11. Bjorklund A, Lindvall O. Dopamine-containing systems in the CNS. In: Bjorklund A, Hokfelt T, editors. Handbook of chemical neuroanatomy, Vol. 2. Classical transmitters in the CNS, Part 1. Amsterdam: Elsevier; 1984. p. 55-122.
12. Blanchard V, Anglade P, Dziewczapolski G, Savasta M, Agid Y, Raisman-Vozari R. Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra. Brain Res 1996; 709: 319-25.
13. Boyes BE, Cumming P, Martin WR, McGeer EG. Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. Life Sci 1986; 39: 2243-52.
14. Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990a; 28: 547-55. Comment in: Ann Neurol 1991; 29: 689-90.
15. Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990a; 28: 547-55. Comment in: Ann Neurol 1991; 29: 689-90.
16. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, et al. The relationship between locomotor disability, autonomie dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomie failure, and Parkinson's disease, studied with PET. Brain 1990b; 113: 1539-52.
17. Cherry SR, Dahlbom M, Hoffman EJ. 3D PET using a conventional multislice tomograph without septa. J Comput Assist Tomogr 1991; 15: 655-68.
18. Cherry SR, Meikle SR, Hoffman EJ. Correction and characterization of scattered events in three-dimensional PET using scanners with retractable septa. J Nucl Med 1993; 34: 671-8.
19. Cumming P, Gjedde A, Reith J. Controversies arising from recent FDOPA articles [letter; comment] [see comments]. J Nucl Med 1997; 38: 1267-71. Comment on: J Nucl Med 1996; 37: 209-22, Comment on: J Nucl Med 1996; 37: 432-7, Comment in: J Nucl Med 1997; 38: 1267-71.
20. Cumming P, Gjedde A, Reith J. Controversies arising from recent FDOPA articles [letter; comment] [see comments]. J Nucl Med 1997; 38: 1267-71. Comment on: J Nucl Med 1996; 37: 209-22, Comment on: J Nucl Med 1996; 37: 432-7, Comment in: J Nucl Med 1997; 38: 1267-71.
21. Cumming P, Gjedde A, Reith J. Controversies arising from recent FDOPA articles [letter; comment] [see comments]. J Nucl Med 1997; 38: 1267-71. Comment on: J Nucl Med 1996; 37: 209-22, Comment on: J Nucl Med 1996; 37: 432-7, Comment in: J Nucl Med 1997; 38: 1267-71.
22. Cumming P, Gjedde A, Reith J. Controversies arising from recent FDOPA articles [letter; comment] [see comments]. J Nucl Med 1997; 38: 1267-71. Comment on: J Nucl Med 1996; 37: 209-22, Comment on: J Nucl Med 1996; 37: 432-7, Comment in: J Nucl Med 1997; 38: 1267-71.
23. Dhawan V, Ishikawa T, Patlak C, Chaly T, Robeson W, Belakhet A, et al. Combined FDOPA and 3OMFD PET studies in Parkinson's disease [see comments]. J Nucl Med 1996; 37: 209-16. Comment in: J Nucl Med 1997; 38: 1267-71.
24. Dhawan V, Ishikawa T, Patlak C, Chaly T, Robeson W, Belakhet A, et al. Combined FDOPA and 3OMFD PET studies in Parkinson's disease [see comments]. J Nucl Med 1996; 37: 209-16. Comment in: J Nucl Med 1997; 38: 1267-71.
25. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in parkinson's disease. Florham Park (NJ): MacMillan Healthcare Information; 1987. p. 153-63.
26. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-301.
27. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
28. Fristen KJ, Frith CD, Liddle PF, Frackowiak RSJ. Plastic transformation of PET images. J Comput Assist Tomogr 1991a; 15: 634-9.
29. Friston KJ, Frith CD, Liddle PF, Frackowiak RS. Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 1991b; 11: 690-9.
30. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995; 2: 189-210.
31. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder, et al. Positron emission tomographic imaging of the dopamine transporter with C-11-WIN 35,428 reveals marked declines in mild Parkinson's disease [see comments]. Ann Neurol 1993; 34: 423-31. Comment in: Ann Neurol 1994; 35: 376-9.
32. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder, et al. Positron emission tomographic imaging of the dopamine transporter with C-11-WIN 35,428 reveals marked declines in mild Parkinson's disease [see comments]. Ann Neurol 1993; 34: 423-31. Comment in: Ann Neurol 1994; 35: 376-9.
33. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983; 305: 137-8.
34. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. [Review]. J Neurol Neurosurg Psychiatry 1988; 51: 745-52.
35. Gjedde A, Reith J, Dyve S, Leger G, Guttman M, Diksic M, et al. Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci USA 1991; 88: 2721-5.
36. Glowinski J, Tassin JP, Thierry AM. The mesocortical-prefrontal dopaminergic neurons. Trends Neurosci 1984; 7: 415-8.
37. Hefti F, Melamed E, Wurtman RJ. The site of dopamine formation in rat striatum after L-dopa administration. J Pharmacol Exp Ther 1981; 217: 189-97.
38. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
39. Holmes AP, Blair RC, Watson JD, Ford I. Nonparametric analysis of statistic images from functional mapping experiments. [Review]. J Cereb Blood Flow Metab 1996; 16: 7-22.
40. Ichise M, Ballinger JR. Physiologic modelling of PET data: quantitative conflict and challenge [editorial; comment]. J Nucl Med 1997; 38: 1266-72. Comment on: J Nucl Med 1997; 38: 1267-2.
41. Ichise M, Ballinger JR. Physiologic modelling of PET data: quantitative conflict and challenge [editorial; comment]. J Nucl Med 1997; 38: 1266-72. Comment on: J Nucl Med 1997; 38: 1267-2.
42. Ishikawa T, Dhawan V, Chaly T, Robeson W, Belakhef A, Mandel F, et al. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. J Cereb Blood Flow Metab 1996a; 16: 854-63.
43. Ishikawa T, Dhawan V, Chaly T, Margouleff C, Robeson W, Dahl JR, et al. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease [see comments]. J Nucl Med 1996b; 37: 216-22. Comment in: J Nucl Med 1997; 38: 1267-71.
44. Ishikawa T, Dhawan V, Chaly T, Margouleff C, Robeson W, Dahl JR, et al. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease [see comments]. J Nucl Med 1996b; 37: 216-22. Comment in: J Nucl Med 1997; 38: 1267-71.
45. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988; 318: 876-80.
46. Kish SJ, Zhong XH, Hornykiewicz O, Haycock JW. Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies? Ann Neurol 1995; 38: 260-4.
47. Kuwabara H, Cumming P, Yasuhara Y, Leger GC, Guttman M, Diksic M, et al. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. J Nucl Med 1995; 36: 1226-31.
48. Le Moal M, Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev 1991; 71: 155-234.
49. Lindvall O, Bjorklund A. The organization of the ascending catecholamine neuron systems in the rat brain as revealed by the glyoxylic fluorescence method. Acta Physiol Scand Suppl 1974; 412: 1-48.
50. Martin WR, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 1989; 26: 535-42.
51. Melamed E, Hefti F, Wurtman RJ. Compensatory mechanisms in the nigrostriatal dopaminergic system in parkinson's disease: studies in an animal model. Is J Med Sci 1982; 18: 159-62.
52. Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995; 59: 597-600.
53. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5: 584-90.
54. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997; 42: 720-6.
55. Pycock CJ, Carter CJ, Kerwin RW. Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat. J Neurochem 1980; 34: 91-9.
56. 18F]fluorodopa studies. In: Myers R, Cunningham V, Bailey DL, Jones T, editors. Quantification of brain function using PET. San Diego: Academic Press; 1996. p. 82-7.
57. 18F]fluorodopa uptake rate using three-dimensional PET. In: Carson R, Daube-Witherspoon ME, Herscovitch P, editors. Quantitative functional brain imaging with positron emission tomography. San Diego: Academic Press; 1998. p. 117-23.
58. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 1994; 91: 11651-4.
59. 11C-flumazenil PET study. Ann Neurol 1996; 40: 188-98.
60. Robb RA, Hanson DP. A software system for interactive and quantitative visualization of multidimensional biomedical images. Australas Phys Eng Sci Med 1991; 14: 9-30.
61. Roberts AC, De Salvia MA, Wilkinson LS, Collins P, Muir JL, Everitt BJ, et al. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine. J Neurosci 1994; 14: 2531-44.
62. Roth RH, Elsworth JD. Biochemical pharmacology of midbrain dopamine neurons. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1995. p. 227-43.
63. Sawle GV, Burn DJ, Morrish PK, Lammertsma AA, Snow BJ, Luthra S, et al. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 1994; 44: 1292-7.
64. Scatton B, Rouquier L, Javoy-Agid F, Agid Y. Dopamine deficiency in the cerebral cortex in Parkinson's disease. Neurology 1982; 32: 1039-40.
65. Simon H, Le Moal M. Mesencephalic dopaminergic neurons: functional role. In: Usdin E, Carlson, Dahlstrom, Engel J, editors: Catecholamines: neuropharmacology and central nervous system. Theoretical aspects. New York: Liss; 1984. p. 293-307.
66. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. Stuttgart: Thieme; 1988.
67. Tison F, Normand E, Jaber M, Aubert I, Bloch B. Aromatic L-amino-acid decarboxylase (DOPA decarboxylase) gene expression in dopaminergic and serotoninergic cells of the rat brainstem. Neurosci Lett 1991; 127: 203-6.
68. 18F]fluorodopa uptake in the human striata in 3D PET with the ETM scatter correction. In: Myers R, Cunningham V, Bailey DL, Jones T, editors. Quantification of brain function using PET. San Diego: Academic Press; 1996. p. 88-92.
69. Weeks RA, Cunningham V, Waters S, Harding AE, Brooks DJ. A comparison of region of interest and statistical parametric mapping analysis in PET ligand work: 111C-diprenorphine in Huntington's disease and Tourette's syndrome. J Cereb Blood Flow Metab 1995; 15 Suppl 1: S41.
70. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications [see comments]. [Review]. Trends Neurosci. 1990; 13: 290-96. Comment in: Trends Neurosci 1991; 14: 182-5.
71. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications [see comments]. [Review]. Trends Neurosci. 1990; 13: 290-96. Comment in: Trends Neurosci 1991; 14: 182-5.